News
Apixaban Noninferior to Enoxaparin for Postoperative VTE Prophylaxis
Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery
Your search for apixaban returned 86 results
News
Rates of Recurrent VTE Compared for Apixaban, Rivaroxaban
Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban
News
Oral Anticoagulants Compared for Gastrointestinal Safety
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
News
AHA: Concentrates Promising for Reversal of Apixaban
Different factor concentrates can reverse some of the alterations in hemostasis attributed to apixaban.
News
Noncompliance to Apixaban for A-Fib Due to Many Factors
Improved communication with patients about cost, bleeding, and monitoring may increase compliance
News
Apixaban Seems Safer Than Rivaroxaban for A-Fib
Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage.
News
Prophylaxis With Apixaban Feasible for Cancer Patients
Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated.
Drugs in the Pipeline
Eliquis Reversal Agent Demonstrates Efficacy in Phase 3 Study
Portola Pharmaceuticals, Bristol-Myers Squibb Company, and Pfizer announced results from the Phase 3 ANNEXA-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors - Apixaban) study with andexanet alfa as a reversal agent for Eliquis (apixaban).
News
Apixaban Beats Aspirin for Stroke Prevention in A-Fib
Apixaban is more effective than aspirin in reducing the risk of repeat stroke and systemic embolism in patients with atrial fibrillation (AF) who are unsuitable for vitamin K antagonists (VKA) therapy.
News
Apixaban Bests Rivaroxaban in “Emulated” Trial of Patients With Afib and VHD
Apixaban and rivaroxaban are both factor Xa inhibitors.
